Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment

JAMA Neurology

Volumn 72, Issue 12, 2015, Pages 1475-1483

  Knopman, David S ^a   Jack, Clifford R ^a   Lundt, Emily S ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Vemuri, Prashanthi ^a   Lowe, Val J ^a   Kantarci, Kejal ^a   Gunter, Jeffrey L ^a   Senjem, Matthew L ^a   Mielke, Michelle M ^a   Machulda, Mary M ^a   Roberts, Rosebud O ^a   Boeve, Bradley F ^a   Jones, David T ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BETA AMYLOIDOSIS; BRAIN LEVEL; BRAIN METABOLISM; BRAIN SIZE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; LATERAL PARIETAL LOBE; LATERAL TEMPORAL LOBE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL PARIETAL LOBE; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; OBSERVATIONAL STUDY; PARIETAL LOBE; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE; VERY ELDERLY; COGNITIVE DYSFUNCTION; COMPLICATION; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOSIS; ANILINE COMPOUNDS; COGNITIVE DYSFUNCTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GRAY MATTER; HUMANS; MALE; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84950285841     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.2323     Document Type: Article

References (46)

1. Wilson RS, Aggarwal NT, Barnes L.L., Mendes de Leon CF, Hebert LE, Evans DA. Cognitive decline in incident Alzheimer disease in a community population. Neurology. 2010;74(12): 951-955.
2. Landau SM, Harvey D, Madison C.M., et al; Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7): 1207-1218.
3. Vemuri P, Wiste HJ, Weigand S.D., et al; Alzheimer's Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73(4): 287-293.
4. Jack CR Jr., Wiste HJ, Vemuri P, et al; Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133(11): 3336-3348.
5. Tosun D, Schuff N, Mathis C.A., Jagust W., Weiner MW; Alzheimer's Disease NeuroImaging Initiative. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134(pt 4): 1077-1088.
6. Chételat G., Villemagne VL, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3): 317-324.
7. Henneman WJ, Sluimer JD, Barnes J, et al Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology. 2009;72(11): 999-1007.
8. Whitwell JL, Shiung MM, Przybelski S.A., et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008;70(7): 512-520.
9. Bernard C, Helmer C, Dilharreguy B., et al. Time course of brain volume changes in the preclinical phase of Alzheimer's disease. Alzheimers Dement. 2014;10(2): 143-151.e1. 24418054
10. Chen K, Langbaum JB, Fleisher A.S., et al; Alzheimer's Disease Neuroimaging Initiative. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2010;51(2): 654-664.
11. Fouquet M, Desgranges B, Landeau B., et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain. 2009;132(pt 8): 2058-2067.
12. Jack CR J.r., Knopman DS, Jagust W.J., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2): 207-216.
13. Knopman DS, Jack CRJ, Wiste HJ, et al Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol. 2013;70(8): 1030-1038.
14. Roberts RO, Geda YE, Knopman D, et al The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008; 30(1): 58-69.
15. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3): 183-194.
16. Roberts RO, Knopman DS, Mielke M.M., et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82(4): 317-325.
17. Roberts RO, Geda YE, Knopman D.S., et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5): 342-351.
18. Petersen RC, Roberts RO, Knopman D.S., et al; The Mayo Clinic Study of Aging. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010;75(10): 889-897.
19. Albert M, DeKosky ST, Dickson D, et al The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.
20. Jack CR J.r., Wiste HJ, Knopman D.S., et al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014; 82(18): 1605-1612.
21. Jack CR J.r., Wiste HJ, Weigand S.D., et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10): 997-1005.
22. Tzourio-Mazoyer N., Landeau B, Papathanassiou D., et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1): 273-289.
23. Whitwell JL, Josephs KA, Murray M.E., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10): 743-749.
24. Knol MJ, Pestman WR, Grobbee DE The (mis)use of overlap of confidence intervals to assess effect modification. Eur J Epidemiol. 2011;26 (4): 253-254.
25. Knopman DS. β-Amyloidosis and neurodegeneration in Alzheimer disease: who's on first? Neurology. 2014;82(20): 1756-1757.
26. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124: 1-38.
27. Greicius MD, Srivastava G, Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101(13): 4637-4642.
28. Knopman DS, Jack CR, Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73(4): 472-480.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4): 239-259.
30. Arnold SE, Hyman BT, Flory J, Damasio A.R., Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1(1): 103-116.
31. Dickerson BC, Stoub TR, Shah R.C., et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16): 1395-1402.
32. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121(2): 171-181.
33. Delacourte A, Sergeant N, Wattez A., et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol. 2002;37(10-11): 1291-1296.
34. Duyckaerts C, Hauw JJ Prevalence, incidence and duration of Braak's stages in the general population: can we know? Neurobiol Aging. 1997;18 (4): 362-369.
35. Murray ME, Graff-Radford NR, Ross O.A., Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9): 785-796.
36. Petersen RC, Aisen P, Boeve B.F., et al. Mild cognitive impairment due to Alzheimer's disease in the community. Ann Neurol. 2013;74(2): 199-208.
37. Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80(11): 1048-1056.
38. van Harten A.C., Smits LL, Teunissen C.E., et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81(16): 1409-1416.
39. Caroli A, Prestia A, Galluzzi S., et al; Alzheimer's Disease Neuroimaging Initiative. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015; 84(5): 508-515.
40. Crary JF, Trojanowski JQ, Schneider J.A., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6): 755-766.
41. Nelson PT, Schmitt FA, Lin Y, et al Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011; 134(pt 5): 1506-1518.
42. Villemagne VL, Burnham S, Bourgeat P., et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4): 357-367.
43. Price JL, Morris JC Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3): 358-368.
44. Mungas D, Tractenberg R, Schneider J.A., Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging. 2014;35(2): 301-308.
45. Jack CR J.r., Wiste HJ, Weigand S.D., et al. Age, sex, and apoe ε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol. 2015;72(5): 511-519.
46. Förster S., Grimmer T, Miederer I., et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry. 2012;71(9): 792-797.